Search

The National Association of School Psychologists' (NASP) Social Justice Committee (SJC) presents a National Book Read to encourage school psychologists and graduate students to come together around a selected text and participate in dialogues within their communities. This annual event, which is accompanied by a range of helpful resources to support discussions, provides a valuable opportunity for participants to engage in critical reflection on their own identities and the systems of oppression that marginalize many communities. The book for 2021-2022 was "Decolonizing Trauma Work: Indigenous Stories and Strategies" by Renee Linklater (2014). Through her own research, personal experiences, and conversations with 10 Indigenous healthcare practitioners, Dr. Linklater shares valuable insights on the concepts of healing, wellness, and effectively supporting the mental health needs of Indigenous communities through a decolonizing approach. School psychology graduate students learned valuable lessons about the history and experiences of Indigenous communities and found empowerment by leading a NASP National Book Read group at William James College in Massachusetts. In this article, they recount their experience of facilitating the book discussion, including what they learned about its application to schools and graduate institutions, as well as its impact on their self-reflection.

Background: It is unclear whether continuing anti-fibrotic therapy until the time of lung transplant increases the risk of complications in patients with idiopathic pulmonary fibrosis. Objectives: To investigate whether the time between discontinuation of anti-fibrotic therapy and lung transplant in patients with idiopathic pulmonary fibrosis affects the risk of complications. Methods: We assessed intra-operative and post-transplant complications among patients with idiopathic pulmonary fibrosis who underwent lung transplant and had been treated with nintedanib or pirfenidone continuously for ⩾ 90 days at listing. Patients were grouped according to whether they had a shorter (⩽ 5 medication half-lives) or longer (> 5 medication half-lives) time between discontinuation of anti-fibrotic medication and transplant. Five half-lives corresponded to 2 days for nintedanib and 1 day for pirfenidone. Results: Among patients taking nintedanib ( n = 107) or pirfenidone ( n = 190), 211 (71.0%) had discontinued anti-fibrotic therapy ⩽ 5 medication half-lives before transplant. Anastomotic and sternal dehiscence occurred only in this group (anastomotic: 11 patients [5.2%], p = 0.031 vs patients with longer time between discontinuation of anti-fibrotic medication and transplant; sternal: 12 patients [5.7%], p = 0.024). No differences were observed in surgical wound dehiscence, length of hospital stay, or survival to discharge between groups with a shorter versus longer time between discontinuation of anti-fibrotic therapy and transplant. Conclusion: Anastomotic and sternal dehiscence only occurred in patients with idiopathic pulmonary fibrosis who discontinued anti-fibrotic therapy

Copyright of Journal of Paper Conservation is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Abstract Purpose Alcohol withdrawal syndrome (AWS) is commonly treated in medical ICUs and typically requires high resource utilization. Dexmedetomidine for AWS has not been extensively investigated, and guidelines regarding its use are lacking. We evaluated the association between dexmedetomidine use in AWS and ICU length of stay (LOS). Methods We performed a multi-institutional retrospective cohort study of patients in the ICU with the primary diagnosis of AWS. ICU LOS of those treated with benzodiazepines alone vs. benzodiazepines plus dexmedetomidine was compared. Negative binomial regression was performed to test whether dexmedetomidine use was associated with increased ICU LOS after adjustment for age, gender, body mass index, and the time between hospital and ICU admission. Results Four hundred thirty-eight patients from eight institutions were included. Patients treated with benzodiazepines plus dexmedetomidine had higher Clinical Institute Withdrawal Assessment for Alcohol scores at ICU admission, spent longer on the medical wards prior to ICU admission, and had longer unadjusted ICU LOS (p

Introduction Chemotherapy-induced peripheral neuropathy (CIPN) may cause functional impairments such as gait or balance disorders, that increase fall risk. Gait disorders may be due to the neurotoxic effect of chemotherapy that causes a prolonged H-reflex latency and inability to inhibit spinal excitability (H-reflex), resulting in increased co-contraction of the lower extremity muscles. Purpose To assess the efficacy of a home-based exercise program on lower extremity muscle co- contraction, spatio-temporal gait factors, and fall risk in a multiple myeloma cancer patient undergoing chemotherapy and experiencing CIPN. Methods A case study was performed on a 67-year-old male diagnosed with multiple myeloma without achieving remission. The participant initially received 5 months of Velcade (bortezomib) which is when they began experiencing CIPN symptoms. The participant then underwent an autologous stem cell transplantation and is currently receiving darzalex, which the participant states exacerbates symptoms of CIPN. The participant has a history of falls secondary to CIPN. The participant initiated a home-based exercise program consisting of resistance, aerobic, balance, and stretching exercises two to three times per week. Outcomes were assessed at baseline and 4 weeks after initiating the exercise program. Results The participant demonstrated increased step length and velocity during gait. EMG data suggested improvements in activation timing and strength of the gastrocnemius and tibialis anterior throughout the gait cycle, as well as improvements in lower-extremity co-contractions. Conclusion This was the first study to investigate the efficacy of a home-based exercise program on lower extremity muscle activation timing and gait characteristics of a cancer patient with CIPN that is currently receiving chemotherapy. The present case study demonstrated that a home-based exercise program may be a feasible intervention to help reduce co-contractions and improve the activation times and amplitudes of lower extremity muscles, which may help improve spatio-temporal gait parameters and reduce fall risk.

Abstract Introduction Components of the hedgehog signaling pathway are upregulated in patients with idiopathic pulmonary fibrosis (IPF). Vismodegib, a small-molecule inhibitor of hedgehog signaling, when used in combination with currently available antifibrotic therapy, may be more efficacious than antifibrotics alone. The objective of this study was to evaluate the safety and tolerability of vismodegib plus pirfenidone in patients with IPF. Methods Twenty-one patients were enrolled in a phase 1b open-label trial to receive vismodegib 150 mg plus pirfenidone 2403 mg/day once daily. Key endpoints were safety, tolerability, and pharmacokinetics. Exploratory endpoints included change from baseline to week 24 in % predicted forced vital capacity (FVC) and University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) scores, as well as pharmacodynamic changes in hedgehog biomarker C-X-C motif chemokine ligand 14 (CXCL14). Results All patients reported at least one treatment-emergent adverse event (AE), most frequently muscle spasms (76.2%). Serious AEs were reported in 14.3% of patients; one event of dehydration was considered related to vismodegib. One patient died due to IPF progression, unrelated to either treatment. More patients discontinued vismodegib than pirfenidone (42.9% vs. 33.3%, respectively). Changes from baseline to week 24 in % predicted FVC and UCSD-SOBQ scores were within known endpoint variability. In contrast to findings in basal cell carcinoma, vismodegib had no effect on circulating CXCL14 levels. Conclusion The safety profile was generally consistent with the known profiles of both drugs, with no new safety signals observed in this small cohort. There was no pharmacodynamic effect on CXCL14 levels. Future development of vismodegib for IPF may be limited due to tolerability issues. Trial Registration ClinicalTrials.gov NCT02648048. Plain Language Summary Plain language summary available for this article. Funding F. Hoffmann-La Roche Ltd. and Genentech, Inc.

Abstract Introduction Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). Real-world data on adverse event (AE) management for pirfenidone are limited. Strategies for managing potential antifibrotic therapy AEs were examined in a sample of US pulmonologists. Methods An online, self-administered survey was fielded to pulmonologists between April 10 and May 17, 2017. Pulmonologists were included if they spent > 20% of their time in direct patient care and had ≥ 5 patients with IPF on antifibrotic therapy. Participants answered questions regarding initiation of pirfenidone, dose titration, and management of potential AEs. Results A total of 169 pulmonologists participated. Gastrointestinal (GI) intolerance was the most important factor in implementing alternative titration schedules for pirfenidone. Approximately three-quarters of pulmonologists recommended the standard titration scheme for starting treatment; however, a range of titration schedules up to 8 weeks were described, with a 4-week schedule being most common. Pulmonologists reported that most patients treated with alternative titration schedules could achieve the full dose of pirfenidone. Pulmonologists who were most effective at mitigating pirfenidone-related GI AEs by advising dosing at mealtimes more frequently recommended taking pirfenidone during a substantial meal than pulmonologists who were less effective. For photosensitivity AEs, pulmonologists recommended sunscreen use, sun avoidance, wearing a hat, and ultraviolet protection factor clothing. Conclusions Pulmonologists reported that alternative titration schedules for initiating pirfenidone were common and can aid in maintaining the full dose. Proposed strategies to ameliorate pirfenidone-related GI and photosensitivity AEs included taking pirfenidone during a substantial meal and minimizing sun exposure, respectively. Funding F. Hoffmann-La Roche Ltd./Genentech, Inc. Plain Language Summary Plain language summary available for this article.

Methods. This observational retrospective cohort study includes 318 ARDS patients extracted from an ICU database between the years of 2001 and 2008. Clinical factors including age, gender, comorbidity score, Sequential Organ Failure Assessment (SOFA) score, and PaO2/FiO2 ratio were chosen for the base model to predict ICU mortality. The RDW value at the time of ARDS diagnosis was added to the base model to determine if it improved its predictive ability. Results. 318 subjects were included; 113 (36%) died in the ICU. AUC for the base model without RDW was 0.76, and 0.78 following the addition of RDW [p=0.048]. The NRI was 0.46 (p=0.001), indicating that, in 46% of patients, the predictive probability of the model was improved by the inclusion of RDW. Conclusions. Adding RDW at time of ARDS diagnosis improved discrimination in a model using 4 clinical factors to predict ICU mortality.

The Boston Marathon is the most popular marathon in the New England region and attracts some of the most qualified athletes participating from the United States and abroad. The race occurs in April, a month in the northeast characterized by unpredictable weather. While there are a number of well described weather-related medical complications that occur during exercise, less is known about noncardiogenic pulmonary edema (NCPE) in marathon runners, a condition that most physician are unfamiliar with. This phenomenon has been described in the literature as a complication of severe hyponatremia and cerebral edema. Here, we describe the case of a healthy athlete who took part in the Boston Marathon in 2018 and presented afterwards with hypothermia and NCPE. We also review the normal cardiopulmonary physiology along with the physiological changes and external factors impacting the respiratory system during exercise. The combination of significant physical exertion, cold and rainy weather and subsequent hypothermia, perhaps along with other less understood factors may have increased the permeability of his lungs and caused NCPE.

Rationale. The impact of emergency department length of stay (EDLOS) upon sepsis outcomes needs clarification. We sought to better understand the relationship between EDLOS and both outcomes and protocol compliance in sepsis. Methods. We performed a retrospective observational study of septic patients admitted to the ICU from the ED between January 2012 and December 2015 in a single tertiary care teaching hospital. 287 patients with severe sepsis and septic shock were included. Study population was divided into patients with EDLOS < 6 hrs (early admission) versus ≥6 hours (delayed admission). We assessed the impact of EDLOS on hospital mortality, compliance with sepsis protocol, and resuscitation. Statistical significance was determined by chi-square test. Results. Of the 287 septic ED patients, 137 (47%) were admitted to the ICU in